Abstract
GE HEALTHCARE TECHNOLOGIES INC will report results on February 04, 2026 Pre-Market; this preview synthesizes last quarter’s actuals and this quarter’s forecasts on revenue, margins, EPS, and segment dynamics alongside the prevailing analyst stance.Market Forecast
Consensus points to GE HEALTHCARE TECHNOLOGIES INC delivering revenue of $5.61 billion this quarter, with adjusted EPS forecast at $1.40 and EBIT at $0.93 billion; year over year, revenue is expected to grow by 5.27%, adjusted EPS by 10.49%, and EBIT by 1.58%. Based on the last-quarter run-rate, the company’s gross profit margin framework sits around the high-30% range at 38.67%, with net profit margin around 8.67%; year-over-year deltas were not disclosed in the forecast dataset.The company’s portfolio outlook remains anchored by Imaging and Advanced Visualization Solutions, supported by Patient Care Solutions and Pharmaceutical Diagnostics. Imaging appears to be the most promising segment near term, with last quarter revenue of $2.35 billion and a pipeline of orders that supports steady year-over-year expansion.
Last Quarter Review
GE HEALTHCARE TECHNOLOGIES INC posted last quarter revenue of $5.14 billion, a gross margin of 38.67%, GAAP net profit attributable to the parent company of $0.45 billion, a net profit margin of 8.67%, and adjusted EPS of $1.07; revenue grew 5.76% year over year, while adjusted EPS declined 6.14% year over year.A notable financial highlight was EBIT of $0.76 billion, which exceeded estimates and reflected disciplined cost execution despite mixed pricing and inflation headwinds. By business line, Imaging generated $2.35 billion, Advanced Visualization Solutions $1.30 billion, Pharmaceutical Diagnostics $0.75 billion, and Patient Care Solutions $0.73 billion, indicating solid breadth across modalities; detailed year-over-year growth by segment was not disclosed.
Current Quarter Outlook
Main business: Broad-based diagnostic and care-delivery platform execution
GE HEALTHCARE TECHNOLOGIES INC’s main business spans Imaging, Advanced Visualization Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions, each tied to hospital and outpatient capital and procedure volumes. For the current quarter, the company’s revenue is projected at $5.61 billion with margins broadly consistent with a high-30% gross margin framework and a mid-to-high single-digit net margin, inferred from the last quarter’s baseline. The key operational swing factors include the cadence of equipment installations, service contract renewals, and contrast media volumes as elective procedures and imaging intensity of care continue to normalize. Management’s recent track record of cost control and mix management provides a foundation to protect margins, particularly as supply chain frictions ease and shipping and component costs stabilize.Demand fundamentals remain linked to macro healthcare utilization and hospital capital budgets, which are benefiting from steady procedure growth and ongoing fleet refresh cycles in CT, MR, and ultrasound. Service and recurring revenue streams help cushion quarter-to-quarter variability in capital orders, and a balanced geographic footprint mitigates isolated regional slowdowns. The company’s EBIT outlook of $0.93 billion and EPS forecast of $1.40 imply modest operating leverage if shipments and service attach rates hold, while pricing discipline and product mix in high-end modalities can offset pockets of input-cost inflation.
Most promising business: Imaging momentum and high-end modality mix
Imaging remains the most promising growth contributor, with prior-quarter revenue of $2.35 billion and a robust innovation cycle across CT, MR, and molecular imaging. Installations in AI-enabled imaging suites and continued adoption of premium-tier systems can support blended average selling prices and expand the installed base for higher-margin service. As backlogs convert and delivery lead times normalize, the unit is positioned to drive mid-single-digit revenue growth alongside a stable service contribution that supports gross margin durability near the company average.Complementing equipment sales, software-driven Advanced Visualization Solutions at $1.30 billion last quarter enhances cross-selling opportunities and deepens stickiness with hospital systems, especially where enterprise imaging platforms are prioritized. The combination of integrated hardware-software offerings and procedural growth in oncology and cardiology imaging supports a constructive view on Imaging’s revenue trajectory this quarter. Execution risks primarily revolve around installation timing and budget release patterns at health systems, but order books and recurring service provide visibility.
Stock price drivers this quarter: Revenue quality, mix, and EPS conversion
Equity investors will focus on whether the company can translate the forecast 5.27% revenue increase to EPS growth of 10.49%, implying incremental margin expansion through mix and cost control. Delivery of high-end Imaging systems and sustained service growth would be read as quality revenue, supporting gross margin resilience around the high-30% level. The EBIT forecast of $0.93 billion makes operating leverage a central narrative; beats would likely require either stronger-than-expected equipment shipments or favorable mix and pricing that flow-through to operating income.Another driver is the cadence in Pharmaceutical Diagnostics, where contrast media volumes can amplify recurring revenue and margin stability; any commentary on new capacity, pricing, or supply chain conditions will influence sentiment. Finally, management’s tone on hospital capital spending, backlog conversion, and pipeline visibility will shape expectations for sequential momentum into the next quarter, with order trends in Imaging serving as a bellwether for the full-year growth framework.
Analyst Opinions
The prevailing institutional stance skews moderately bullish, with a majority emphasizing resilient demand in Imaging and recurring revenue contributions that support margin stability and EPS growth in line with the current quarter’s forecast. Analysts point to the prior quarter’s top-line outperformance and EBIT beat as evidence that cost actions and pricing can underpin operating leverage as supply conditions normalize. Commentary highlights that mid-single-digit revenue growth paired with disciplined expense control can support high-single-digit to low-double-digit EPS growth, aligning with the forecasted 10.49% increase in adjusted EPS.Widely followed analyst houses emphasize the durability of hospital imaging upgrades and software-driven differentiation within enterprise imaging stacks, framing upside potential if backlog conversion accelerates. They also note that the company’s exposure to procedure volumes and recurring service revenues helps dampen volatility relative to pure equipment cycles. On balance, the majority view remains constructive heading into the print, contingent on Imaging mix, service attach rates, and execution on cost productivity to deliver the forecast EBIT and EPS trajectory.
Comments